Register Login
Register to leave comments
  • News bot Aug. 12, 2026, 8:27 p.m.

    📋 ALLOGENE THERAPEUTICS, INC. (ALLO) - Financial Results

    Filing Date: 2026-08-12

    Accepted: 2026-08-12 16:12:27

    Event Type: Financial Results

    Event Details:

    ALLOGENE THERAPEUTICS, INC. (ALLO) Reports the reporting period Financial Results ALLOGENE THERAPEUTICS, INC. (ALLO) announced its financial results for the period ending the reporting period. Key Financial Highlights:
    • Revenue: 4640
    • Net Income: Not disclosed
    • EPS: Not disclosed
    • Cash and equivalents: 423590
      • targeting anti-CD19/CD70 AlloCAR T product incorporating the Company’s proprietary Dagger® technology. The product was designed to address allogeneic rejection by targeting activated CD70-positive host T cells, with the goal of supporting CAR T-cell expansion while reducing or eliminating the need for conventional chemotherapy-based lymphodepletion.The ongoing Phase 1 RESOLUTION trial is a dose-escalation study evaluating cell dose of ALLO-329 and the role played by Dagger with and without lymphodepletion across multiple autoimmune indications, including systemic lupus erythematosus, scleroderma, and inflammatory myositis.Enrollment continues at a brisk pace across cohorts, dose levels and lymphodepletion strategies. The Company remains on track to provide a clinical and translational update in the fourth quarter of 2026
      • Anticipated in Mid-2027
      • Expected by Year-End, Further Supporting Enrollment◦Next Update Anticipated in Mid-2027

    📊 Key Financial Metrics (Year-over-Year Comparison):

    Metric 2026 2025 Change ($) Change (%)
    Operating Expenses Loss From Operations -46.92K -56.82K $9.90K +17.42%
    Other Income Expenses Net Interest Expense -343.00 -268.00 $-75.00 -27.99%
    Other Income Expenses Net Total Other Income Expense 4.24K 5.88K $-1.63K -27.79%
    Other Income Expenses Net Net Loss -42.68K -42.68K $0.00 +0.00%
    Other Income Expenses Net Net Loss Per Share -0.13 -0.13 $0.00 +0.00%
    Other Income Expenses Net Weighted Average Shares 328.93M 218.93M $110.00M +50.24%
    Revenue 4.64K 4.64K $0.00 +0.00%
    Loss from Operations -46.92K -56.82K $9.90K +17.42%
    Other Income, Net 4.65K 6.19K $-1.54K -24.89%
    Interest Expense -343.00 -268.00 $-75.00 -27.99%
    Net Loss -42.68K -42.68K $0.00 +0.00%

    💼 Business Developments:

    • Partnership
    • Acquisition: Not available
    • Licensing: Not available
    • Regulatory Approval: Not available
    • Executive Changes: Not available

    Structured Data:

    • Company Name: ALLOGENE THERAPEUTICS, INC.
    • Ticker Symbol: ALLO

Search

News categories